Experimental cell therapy targets Hard-to-Treat leukemia
NCT ID NCT07491263
First seen Mar 30, 2026 · Last updated May 18, 2026 · Updated 9 times
Summary
This early-stage study tests a new treatment called QH103 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-γδ T cells) to find and attack cancer cells. The main goal is to check if the treatment is safe and tolerable in just 6 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CD19-POSITIVE B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of fujian medical university
Fuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.